

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1509)

**(1) QUARTERLY UPDATE ANNOUNCEMENT
ON THE RESUMPTION PROGRESS;
(2) DELAY IN DESPATCH OF THE ANNUAL REPORTS FOR
THE YEARS ENDED 31 DECEMBER 2018 AND 2019 AND THE
INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2019;
(3) DELAY IN DESPATCH OF
THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2019;
AND
(4) CONTINUED SUSPENSION OF TRADING**

This announcement is made by Harmonicare Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.24A of the Listing Rules.

Reference is made to (1) the announcement of the Company dated 28 March 2019 in relation to its delay in the publication of the 2018 Annual Results and despatch of the 2018 Annual Report, (2) the announcement of the Company dated 7 May 2019 in relation to its publication of unaudited management accounts for the year ended 31 December 2018 and the engagement of its Internal Control Consultant, (3) the announcement of the Company dated 12 June 2019 in relation to the guidance received from the Stock Exchange regarding the resumption of trading of the Company’s shares on the Stock Exchange, (4) the quarterly update announcement of the Company dated 28 June 2019 in relation to, among others, its resumption progress, (5) the update announcement of the Company dated 31 July 2019 in relation to the progress of its internal control review, (6) the announcement of the Company dated 30 August 2019 in relation to, among others, further delay in publication of the 2018 Annual Results and the delay in publication of the 2019 Interim Results, (7) the quarterly update announcement of the Company dated 29 September 2019 in relation to, among others, its resumption progress, (8) the quarterly update announcement of the Company dated 24 December 2019, (9) the voluntary announcement of the Company dated 10 March 2020 on the impact of novel coronavirus (COVID-19) epidemic on the Group’s business operations, (10) the supplemental announcement of the Company dated 25 March 2020 on the results of its internal control review, (11) the quarterly update announcement of the Company dated 31 March 2020 in relation to, among others, its resumption progress (the “**Quarterly Update Announcement**”) and (12) the announcement of the Company dated 15 June 2020 in relation to, among others, the cessation of construction of a subsidiary (the “**Cessation Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the Quarterly Update Announcement unless otherwise stated herein.

BUSINESS OPERATION

The Group is mainly engaged in providing high-quality healthcare services to women and children. The Group has continued its normal business operations since the suspension of trading in the Company's shares. Since 1 April 2019 and up to the date of this announcement, there has been no major change on the business operations of the Group.

As disclosed in the Quarterly Update Announcement, as a result of the Epidemic, there was a decline in the Group's performance in the first quarter of 2020. So far, the areas where some of the Group's hospitals are located are still affected by the Epidemic. According to the Group's unaudited management accounts, revenue from January to May 2020 decreased by 42.66% year-on-year, and net profit decreased by 22.61% year-on-year. Under such special circumstances, the Group has used its best endeavors to minimize any negative economic impact on the Group. The Board will closely monitor the situation of the Epidemic and react actively to its impact on the financial position of the Group. The Company will take appropriate measures as necessary.

As disclosed in the Cessation Announcement, Heilongjiang Zhongda HarMonicare Hospital Co., Ltd.* (黑龍江中大和美婦兒醫院有限公司), a company established in the PRC with limited liability and a 95% owned subsidiary of the Company, has ceased its construction. It entered into a termination agreement of the lease on 15 June 2020 and started the liquidation process thereafter.

UPDATE ON THE TIMELINE IN FULFILLING THE RESUMPTION CONDITIONS

As disclosed in the Quarterly Update Announcement, the Company is in progress of cooperating with ZHONGHUI ANDA CPA Limited to solve the outstanding matters previously identified by Deloitte. Further, due to travel and work restrictions in connection with the Epidemic, the reporting and audit processes of the Group's outstanding financial statements are significantly affected. As a result, the Company expects further delay in the publication of its outstanding financial results and despatch of its outstanding financial reports.

The following table sets forth the pending events and update in the expected timetable for resumption of trading in the shares of the Company:

Key event	Timetable
Publication of the 2018 Annual Results	Subject to further assessment by the Board
Publication of the 2018 Annual Report	Subject to further assessment by the Board
Publication of the 2019 Interim Results	Subject to further assessment by the Board
Publication of the 2019 Interim Report	Subject to further assessment by the Board
Publication of the 2019 Annual Results	Subject to further assessment by the Board
Publication of the 2019 Annual Report	Subject to further assessment by the Board
Resumption of trading in the shares of the Company	Subject to further assessment by the Board

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2019. Trading in the Shares will remain suspended until further notice.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Harmonicare Medical Holdings Limited
Lin Yuming
Chairman, Executive Director and President

Hong Kong, 30 June 2020

As at the date of this announcement, the executive Directors are Mr. Lin Yuming and Mr. Fang Zhifeng; the non-executive Directors are Mr. Lin Yuguo, Mr. Qiu Jianwei and Mr. Xu Jun; and the independent non-executive Directors are Mr. Kong Aiguo, Ms. Fang Lan and Mr. Cai Jiangnan.